Skip to main content
Search form
Search
Subscribe to newsletter +
European Association of Hospital Pharmacists
Menu
Main menu
Home
About Us
Who we are
Board
Staff
Students
Transparency
Contact Information
Call for Expressions of Interest
Members
Associate membership
News
Press Releases
EAHP Newsletters
EAHP in the news
Multimedia Gallery
Events
Calendar
Academy
Synergy Masterclass
EAHP BOOST
Congresses
General Assemblies
Accreditations
EAHP Synergy Certification Courses
Open Learning
Get Involved
Sponsors and partners
HP Practice
EAHP COVID-19 Resource Centre
European Statements of Hospital Pharmacy
What hospital pharmacists do
EAHP-ESCP Oath to Society
FIP global statements
National legislation on hospital pharmacy
Good Practice Initiatives
Common training framework
Environmental Sustainability
European Council for Pharmacy Education Accreditation
Investigation of the hospital pharmacy profession in Europe
Hospital Pharmacy Day
SIGs
Controlled Substances Management
Special Interest Group on Investigation of medication errors and efficiency in oncology
Automated Medication Management
Working Towards Eliminating Avoidable Harm
Hazardous Medicinal Products
Hospital Pharmacist’s Preparedness for in-vivo gene therapy medicinal products
Investigation of Medication Errors in Intensive Care Units
Use of Prefilled Syringes in Intensive Care Units and Operating Theaters
Policy
Resources
Consultations
Position Papers
Get involved and keep up to date
Access to Medicines
Ageing society
Infectious Diseases and AMR
ATMPs
Bar coding medicines to the single unit
Biosimilar medicines
Clinical trials
Digital Health
EMA - EAHP collaboration
European List of Emergency Medicines
Falsified Medicines
Hazardous Medicinal Products
Hospital Pharmacy Specialisation
Medical device regulation
Medicines shortages
Patient safety
Pharmaceuticals in the environment
Pharmacy preparations and compounding
Procurement
Public spending austerity
SmPC
Vaccination
Workforce
Statements
GPIs
Publications
2019 EP Election Manifesto
General information
EAHP Annual report
European Journals of Hospital Pharmacy
EAHP Surveys of HP practice
EAHP History Book
Practical Pharmaceutics
Congress presentation webcasts
2024 European Parliament Election Manifesto
Member Center
You are here
Home
Drug Information and Pharmacotherapy
DI-001
ANALYSIS OF THE USE, EFFECTIVENESS AND SAFETY OF TREATMENT WITH TRASTUZUMAB-EMTANSINE IN METASTATIC BREAST CANCER
DI-094
TREATMENT OF PULMONARY EMPHYSEMA ASSOCIATED WITH ALPHA-1-ANTITRYPSIN DEFICIENCY
DI-093
PREDICTORS OF NON-ADHERENCE TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN HIV-INFECTED PATIENTS
DI-092
POPULATION ATTRIBUTABLE RISK OF HIP FRACTURES IN ANTIDEPRESSANT USERS IN HUNGARY AND ESTIMATION OF THE RELEVANT COST CONSEQUENCES
DI-091
ASSESSMENT OF AN EDUCATION PROGRAM FOR PATIENTS TREATED WITH ORAL ANTICOAGULANTS IN A CARDIOLOGY DEPARTMENT: A PILOT STUDY
DI-089
EFFECTIVENESS OF ABIRATERONE IN PROSTATE CANCER IN CLINICAL PRACTICE
DI-088
SINGLE-TABLET REGIMEN TENOFOVIR/ EMTRICITABINE/ RILPIVIRINE: ONE YEAR'S EXPERIENCE
DI-087
SPONTANEOUS REPORTING OF ADVERSE DRUG REACTIONS IN A SECOND LEVEL HOSPITAL: IS PHARMACOVIGILANCE WELL TARGETED?
DI-086
INFLUENCE OF THE RECOMMENDATIONS OF THE EUROPEAN MEDICINES AGENCY REGARDING THE MODIFICATION OF THE PRESCRIPTION PATTERN OF METOCLOPRAMIDE
DI-085
EVOLUTION OF ANTIRETROVIRAL PRESCRIPTIONS IN TREATMENT-NAÏVE HIV-INFECTED PATIENTS
DI-084
COST-UTILITY OF SOFOSBUVIR-BASED TREATMENT FOR UNTREATED GENOTYPE 1 AND 3 HEPATITIS C PATIENTS
DI-083
AMPHOTERICIN B TOPICAL TREATMENT OF PLEURAL ASPERGILLOSIS: A CASE REPORT
DI-082
IMPROVEMENT IN THE LIPID PROFILE OF HIV-INFECTED PATIENTS AFTER SWITCHING TO RILPIVIRINE/EMTRICITABINE/TENOFOVIR
DI-081
ORAL CHEMOTHERAPY: INCIDENCE AND DESCRIPTION OF POTENTIAL INTERACTIONS BETWEEN DRUGS AND FOOD
DI-079
EFFECTIVENESS OF TREATMENT WITH IMMUNOGLOBULIN IN PATIENTS WITH ITP
Pages
« first
‹ previous
…
5
6
7
8
9
10
11
12
13
…
next ›
last »
Follow Us